<DOC>
	<DOCNO>NCT01958073</DOCNO>
	<brief_summary>The investigator would like know use vaginally apply estrogen prevent problem repeat urinary tract infection ( UTI ) woman go menopause . The investigator use two form vaginal estrogen available prescription ( ring cream ) compare efficacy placebo ( without active ingredient ) . The investigator go look vaginal estrogen prevent UTIs altogether also number UTIs group experience 6 month period . After 6 month , subject receive vaginal estrogen woman non-active treatment randomize either estrogen ring cream . The investigator able compare number UTIs active vaginal estrogen treatment within subject start placebo . The investigator also go look quality life treatment use questionnaire whether subject stop use treatment use direct ( compliance ) .</brief_summary>
	<brief_title>Vaginal Estrogen Prevention Recurrent Urinary Tract Infection Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Postmenopausal status define amenorrhea &gt; 12 month , OR history bilateral salpingoophrectomy , OR patient hysterectomy define menopausal symptom &gt; 1 year OR age &gt; 55 2 . Documented recurrent UTIs ( 3 last year 2 last 6 month ) one UTI must document culture , others may document urinalysis 3 . Ability provide inform consent 1 . Use investigational drug device within thirty day screen 2 . Urologic surgery within past 3 month screen plan surgery within one year screen 3 . Diagnosis Interstitial Cystitis/painful bladder syndrome 4 . History urinary tract infection require use IV antibiotic one oral antibiotic available treatment , risk treatment vaginal estrogen deem unacceptable principle investigator secondary severity prior urinary tract infection 5 . Known etiology infection , limited : kidney bladder stone , enterovaginal/vesical fistula , fecal incontinence , intermittent catheterization , indwell catheter , poorly control diabetes 6 . Urothelial cancer 7 . Actively treated estrogen sensitive tumor ( breast endometrial cancer ) 8 . Undiagnosed vaginal bleeding 9 . Inability use vaginal ring ( secondary advance prolapse shorten vaginal length ) 10 . Any medical reason investigator deem incompatible treatment vaginal estrogen 11 . Prolapse require pessary use Deferral Criteria 1 . Undiagnosed hematuria may enroll malignancy rule 2 . Use progestin contain intrauterine device use vaginal androgen , estrogens progestin within 3 month enrollment may enroll wash 3 . Use drugs/supplements know prevent UTIs ( ie cranberry product , prophylactic antibiotic , methenamine hippurate ) 1 month prior enrollment may enroll wash still meet inclusion criterion . 4 . History estrogen sensitive tumor ( breast endometrial cancer ) require approval subject 's primary oncologist primary care physician</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Recurrent Urinary Tract Infection</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Vaginal Estrogen</keyword>
</DOC>